Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Feb 3, 2026
Rezurock® now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD)
Nov 10, 2025
Eight out of 10 infants and newborns in Canada have access to RSV prevention with Beyfortus® this season
Nov 6, 2025
Rezurock® now covered in Quebec for people living with chronic graft-versus-host disease (GVHD)
Nov 3, 2025
Dupixent® approved in Canada as targeted therapy for chronic spontaneous urticaria (CSU)
Oct 22, 2025
Dupixent® (dupilumab injection) approved in Canada for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD)
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
23
»
